Antipneumococcal activities of GAR-936 (a new glycylcycline) compared to those of nine other agents against penicillin-susceptible and -resistant pneumococci.
GAR-936, a new glycylcycline, had lower MICs (< or =0.016 to 0.125 microg/ml) for 201 penicillin- and tetracycline-susceptible and -resistant pneumococcal strains than tetracycline (< or = 0.06 to 128 microg/ml), minocycline (< or =0.06 to 16.0 microg/ml), or doxycycline (< or =0.06 to 32.0 microg/ml). GAR-936 was also bactericidal against 11 of 12 strains tested at the MIC after 24 h, with significant kill rates at earlier time points.
Hoellman
D B
DB
Department of Pathology, Hershey Medical Center, Hershey, Pennsylvania 17033, USA.
Pankuch
G A
GA
Jacobs
M R
MR
Appelbaum
P C
PC
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D015169:Colony Count, Microbial; D008826:Microbial Sensitivity Tests; D008911:Minocycline / Q000031:analogs & derivatives* / Q000494:pharmacology; D010403:Penicillin Resistance; D013296:Streptococcus pneumoniae / Q000187:drug effects*; D000078304:Tigecycline; D013997:Time Factors
D000900:Anti-Bacterial Agents; D000078304:Tigecycline; D008911:Minocycline